Loading clinical trials...
Loading clinical trials...
A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Conditions
Interventions
LHC165
PDR001
Locations
9
United States
UCLA
Los Angeles, California, United States
MD Anderson Cancer Center
Houston, Texas, United States
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Start Date
January 31, 2018
Primary Completion Date
June 30, 2022
Completion Date
June 30, 2022
Last Updated
June 20, 2024
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06716138
NCT06307795
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions